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Rapport de synthèse 
Combining bone resorption markers and heel quantitative ultrasound to 
discriminate between fracture cases and controls 
L'ostéoporose est reconnue comme un problème majeur de santé publique. Comme 
il existe actuellement des traitements préventifs efficaces pour minimiser le risque de 
fracture, il est essentiel de développer des nouvelles stratégies de détection des 
femmes à risque de fracture. Les marqueurs spécifiques du remodelage osseux 
dosés dans les urines ainsi que les ultrasons quantitatifs du talon ont été étudiés 
comme outils cliniques pour prédire le risque fracturaire chez les femmes âgées. Il 
n'existe cependant que très peu de donnée sur la combinaison de ces deux outils 
pour améliorer la prédiction du risque de fracture. 
Cette étude cas-contrôle, réalisée chez 368 femmes âgées de 76 ans en moyenne 
d'une cohorte suisse de femmes ambulatoires, évalue la capacité discriminative -
entre 195 femmes avec fracture non-vertébrale à bas traumatisme et 173 femmes 
sans fractures - de deux marqueurs urinaires de la résorption osseuse, les 
pyridinolines et les deoxypyridinolines, ainsi que deux ultrasons quantitatifs du talon, 
le Achilles+ (GE-Lunar, Madison, USA) et le Sahara (Hologic, Waltham, USA). Les 
195 patientes avec une fracture ont été choisies identiques aux 173 contrôles 
concernant l'age, l'indice de masse corporel, le centre médical et la durée de suivi 
jusqu'à la fracture. 
Cette étude montre que les marqueurs urinaires de la résorption osseuse ont une 
capacité environ identique aux ultrasons quantitatifs du talon pour discriminer entre 
les patientes avec fracture non-vertébrale à bas traumatisme et les contrôles. La 
combinaison des deux tests n'est cependant pas plus performante qu'un seul test. 
Les résultats de cette étude peuvent aider à concevoir les futures stratégies de 
détection du risque tracturaire chez les femmes âgées, qui intègrent notamment des 
facteurs de risque cliniques, radiologiques et biochimiques. 
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Abstract 
Sum111a1y This nested case-control analysis of a Swiss 
ambulat01y cohort of elderly women assessed the discrim-
inat01y power of urinaiy markers of bone resorption and 
heel quantitative ultrasound for non-vertebral fractures. The 
tests all discriminated between cases and controls, but 
combining the two strategies yielded no additional relevant 
information. 
Introduction Data are limited regarding the combination of 
bone resorption markers and heel quantitative bone ultra-
sound (QUS) in the detection of women at risk for fracture. 
Methods In a nested case-control analysis, we studied 368 
women (mean age 76.2±3.2 years), 195 with low-trauma 
non-vertebral fractures and 173 without, matched for age, 
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BMI, medical center, and follow-up duration, from a 
prospective study designed to predict fractures. Urinaiy total 
pyridinolines (PYD) and deoxypyridinolines (DPD) were 
measured by high performance liquid chromatography. Ali 
women underwent bone evaluations using Achilles+ and 
Sahara heel QUS. 
Results Areas under the receiver operating-characteristic 
curve (AUC) for discriminative models of the fracture 
group, with 95% confidence intervals, were 0.62 (0.56-
0.68) and 0.59 (0.53-0.65) for PYD and DPD, and 0.64 
(0.58-0.69) and 0.65 (0.59-0.71) for Achilles+ and Sahara 
QUS, respectively. The combination of resorption markers 
and QUS added no significant discriminat01y inf01mation 
to either measurement alone with an AUC of 0.66 (0.60-
0.71) for Achilles+ with PYD and 0.68 (0.62-0.73) for 
Sahara with PYD. 
Conclusions Urinary bone resorption markers and QUS are 
equally discriminatory between non-vertebral fracture 
patients and controls. However, the combination of bone 
resorption markers and QUS is not better than either test 
used atone. 
Keywords Bone markers · Bone ultrasound · Fracture risk · 
Nested case-control study · Osteoporosis 
Introduction 
Osteoporosis bas been recognized as a major public health 
problem. In Western countries, hip fracture incidence rates 
among white women are the highest worldwide [1]. Since 
effective treatments exist to minimize fracture risk, it is 
essential that new screening strategies are developed to 
detect women at risk. Specific biochemical markers ofbone 
turnover and ultrasonic measurements of bone have been 
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proposed as risk factors that independently add information 
in the assessment of fracture probability. 
The measurement of bone resorption using urinaty 
biochemical markers has been studied as a clinical tool 
with which to predict fracture risk in postmenopausal 
women [2, 3]. In prospective nested case-control analyses 
[4-6] and cohort studies [7-10], elevated bone resorption 
markers have been found to be associated with an increased 
risk of osteoporosis-related fractures. For the identification 
of high-risk individuals, combination strategies, using bone 
markers, and bone minerai density (BMD) have been 
shown to increase test specificity without any loss in 
sensitivity [11]. 
Quantitative ulh'asound (QUS) of the calcaneus has been 
shown in many prospective studies to predict vertebral and 
non-vertebral fracture risk independent of BMD [ l 2-18]. 
Comparing different QUS in the same population, we 
previously demonstrated that two heel QUS devices-the 
Achilles+ (GE-Lunar, Madison, WI, USA) and the Sahara 
(Hologic, Waltham, MA, USA)--are good predictors of hip 
and non-vertebral fracture risk, with no detectable differ-
ence between the two devices [19, 20]. 
However, few data exist with respect to the combination 
of bone resorption markers and heel QUS, in terms of 
identifying women at risk for fractures. To investigate this 
issue further, we perfonned nested case-control analysis of 
a Swiss cohort of post-menopausal women, comparing the 
results obtained using urinmy levels of two bone resorption 
markers and two heel QUS devices, in women who had 
sustained a low-trauma hip or mm fracture versus those 
without fractures. 
Methods 
Subjects 
Between the autumn of 1997 and summer of 1999, 7,609 
ambulatmy Swiss women, with a mean age of 75.3± 
3 .1 years, were enrolled voluntarily in the Swiss Evaluation 
of Methods of Measuring Osteoporotic Fracture Risk 
(SEMOF) study [19, 21]. This prospective, multicenter 
study compared three different QUS devices-two measur-
ing the heel and one the phalanges-as potential predictors 
of non-vertebral fracture risk. The SEMOF study was 
financed by the Association of Swiss Health Insurance, and 
the protocol was accepted by the Swiss Ethics Committee of 
Medical Sciences. Written informed consent was obtained 
from all women. Participants were recrnited from official 
state registries and asked to visit one of the Swiss 
osteoporosis center certified to use the QUS devices. 
Women able to walk and independent in their daily 
activities were included; those with a hip fracture history 
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or bilateral hip replacement were excluded. At baseline, 
participants underwent a face-to-face interview, during 
which they were asked about varions osteoporosis risk 
factors, including persona! fracture histmy, followed by a 
clinical examination that included calculation of body mass 
index (BMI). All women also underwent heel QUS. After 
the baseline visit, all women were asked to send back a 
second fasting sample of urine for the measurement of 
urinary bone markers. Details of sh1dy methods and patient 
characteristics have been reported previously [21, 22]. 
Identification of fractures 
According to the protocol of the SEMOF study, information 
on ve1tebral fractures was not collected. We considered 
major osteoporotic fractures (excluding vertebral fracrures), 
defined as low-trauma hip, distal forearm, or proximal 
humerus fractures [23]. Low-trauma fractures were defined 
as spontaneous or as a consequence of a fall from standing 
height or Jess. A medical report from the patient's attending 
physician was obtained to confirm each frachll'e. The 
validity of fracrure information has been demonstrated 
previously [24]. 
Nested case-control design 
To assess the predictive power of markers of bone 
resorption, 250 women with non-vertebral frachlfes and 
250 controls matched for age, BMI, hospital, and follow-up 
duration were selected randomly and included in a nested 
case-control study. From the 500 selected women, 406 
urine samples were qualitatively and quantitatively analyz-
able. Thirty-eight women were excluded because they were 
receiving hormone replacement therapy or antiresorptive 
therapy, like a bisphosphonate. Ultimately, 368 women-
195 fracture cases and 173 controls-were included in the 
analysis, with a mean age of 76.2±3.2 years and a mean 
follow-up of 2.3±1.2 years. Among the 195 fracture cases, 
62 were hip fractures and 133 were frachll'es of the distal 
forearm or proximal humerus. 
Urine sampling 
Urinmy samples were collected between the auh1mn of 
1997 and summer of 1999. Bach pa1ticipant in the SEMOF 
cohort received a standard plastic container and instructions 
on how to collect a urine specimen at home. They were 
asked, following standard protocol, to send the fasting 
second morning specimen of urine to the Instirute for 
Clinical Chemistry and Hematology (State Hospital of St. 
Gall). To minimize preanalysis variability, samples were 
stored frozen at -20°C, light protected, and never thawed 
until the analyses were done in 2004. 
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Measurement of bone markers 
Two crosslinked collagen components, total urinaiy pyr-
idinoline (PYD) and deoxypyridinoline (DPD), were 
measured by high performance liquid chromatography 
(HPLC). Ail analyses were conducted using the same 
commercial test kit: the BIO-RAD Pyridinium-Crosslinks 
by HPLC, a highly specific technique designed to isolate 
and detect pyridinium crosslinks in urine [25]. Brietly, a 
150-µl urine sample, mixed with an internal standard, was 
hydrolyzed with 200 µl HCL 12 N over 16 h at 100°C. 
After dilution, cold samples were applied to a cellulose 
column for extraction of interfering substances, and 
pyridinium crosslinks were eluted from the column. For 
HPLC analysis, separation of PYD and DPD was obtained 
by chromatography on a reverse phase column with 
isocratic elution. The elements' natural fluorescence was 
detected by spectrofluorometry. Quantitative dete1mination 
was based upon comparisons against an external standard, 
measured in parallel. Ali results were expressed as cross-
links/creatinine (pmol/µmol). Mean precision petformance 
for the BIO-RAD Pyridinium-Crosslinks test given by the 
manufacturer reached a percentage coefficient of variation 
of 6.4% for PYD and 6.6% for DPD [25]. 
QUS 
Achilles+ is a heel water-bath ultrasound system. Achilles+ 
generates a band of frequencies from 200 to 600 kHz. It 
measures broadband ultrasound attenuation (BUA) 
expressed in dB/MHz, with a reported standardized 
coefficient of variation (SCV) of 5.8%, and the speed of 
sound (SOS) expressed in mis, with a SCV of 4.2% [26]. A 
third variable, the stiffness index (SI) with a SCV of 2.6%, 
is calculated automatically, using the equation: 
Si= (0.67 x BUA) + (0.28 x SOS) - 420, expressed as 
a percentage of the values obtained by the manufacturer 
in a young adult population [27]. 
The Sahara QUS is a dty system ultrasound using an oil-
based coupling gel. The frequencies of the ultrasounds 
range from 200 to 600 kHz. The two calculated variables are 
the BUA with a SCV of 4.4% and the SOS with a SCV of 
4.3% [26]. An additional variable, the quantitative ultrasound 
index (QUI) with a SCVof3.2%, is calculated automatically, 
using the equation: QUI= 0.41 x (BUA +SOS) - 571; 
The Result of this equation is expressed in dimensionless 
units [28]. 
Statistical analysis 
Statistical tests used to compare fracture cases and controls 
for each baseline characteristic were Student's t tests and 
Pearson's chi square tests, as appropriate. To estimate the 
predictive power of each test alone and of tests in 
combination, with respect to discriminating non-vertebral 
fractures, areas under the receiving operating characteristic 
curves (AUC) were calculated with 95% confidence 
intervals (95% CI). Differences in AUC of the predictive 
scores derived from the logistic regression with combina-
tions of independent variables were tested statistically using 
the algorithm described in Delong et al. [29]. As no 
consensus exists about the threshold values for increased 
bone turnover, we studied two commonly used thresholds, 
the highest qua1tile against the three lowest and the 
premenopausal upper reference limit. The peak values for 
the premenopausal range were generated by the BIO-RAD 
laborat01y kit and have been defined as per the Center for 
Disease Control and Prevention in Atlanta [25]. Similarly, 
because of the lack of established risk thresholds for QUS 
in clinical practice, we studied two different threshold 
values for each QUS device, the lowest quartile against the 
three highest, and a cutoff value that was able to detect, 
with a specificity of 80%, women at high-risk for fracture 
or with known osteoporosis of the hip in the SEMOF 
cohort [20]. According to these thresholds, we estimated 
odds ratios (OR) with 95% CI for those with high versus 
low bone marker levels and for those with low versus 
high QUS measurements. We estimated OR for serial 
(i.e., consecutive) combinations of the two diagnostic tests, 
using the 'and' logical operator. Ali analyses were 
performed using Stata 9.2 statistical software (Stata 
Corporation, College Station, TX, USA). 
Results 
Baseline characteristics of the 195 non-vertebral fracture 
patients and 173 controls are presented in Table 1. Mean 
age was 76.2±3.2 years. Women who had sustained a non-
ve1tebral fracture had statistically higher levels of bone 
resorption markers and lower QUS measurements than 
controls. As the prevalence of past fracture was not 
statistically different between fracture patients and controls, 
and adjusted OR for this factor were comparable to non-
adjusted OR (data not shown), we did not enter this 
variable into the logistic mode!. In sub-analyses, consider-
ing women with arm fractures only, there were no statistical 
differences in DPD levels compared to controls (data not 
shown). 
For each individual test-PYD, DPD, SOS, BUA, SI, 
and QUI-the AUC revealed an overall discriminatory 
capacity for the hip or arm fracture group (Table 2). Sahara 
QUI had the higher discriminat01y power, with an AUC 
(95%CI) of 0.65 (0.59-0.71); however, no test was 
statistically better than the other. As the discriminatory 
capacity of the different QUS parameters was not statisti-
~ Springer 
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Table 1 Baseline characteristics of low-h·auma fracture patients and controls 
Control group Hip or arm fracture p Hip fracture p 
group value a group valuea 
Number 173 195 62 
Age, years 76.3±3.2 76.2±3.1 0.78 76.9±3.0 0.18 
BMI, kg/m2 25.3±4.3 25.5±4.1 0.63 24.3±4.2 0.10 
Histo1y of past fracture 46.2 (80) 54.4 (106) 0.14 53.2 (33) 0.34 
Urinaiy markers of bone PYD, pmol/~1mol 73.1±23.5 85.9±33.3 0.00 99.6±36.7 0.00 
resorption DPD, pmol/~11110! 14.6±6.1 16.4±7.3 0.01 19.0±9.1 0.00 
Achilles+ heel ultrasound BUA, dB/MHz 99.4±10.0 95.1±9.4 0.00 92.1±8.7 0.00 
SOS, mis 1509.3± 28.6 1495.6 ± 24.2 0.00 1490.9±26.9 0.00 
SI,% 68.9± 13.4 62.2 ±12.0 0.00 59.0±12.1 0.00 
Sahara heel ultrasound BUA, dB/MHz 57.2±16.8 49.1±12.7 0.00 47.0±12.6 0.00 
SOS, m/s 1517.2±29.4 1501.9±22.l 0.00 1499.1±25.8 0.00 
QUI, unit 74.5± 18.4 64.9±13.7 0.00 62.9±15.l 0.00 
Values are reported as mean ± standard deviation or percentage (number) 
BMI body mass index, BUA broadband ultrasound attenuation, SOS speed of sound, SI stiffness index, QUI quantitative ultrasound index, DPD 
deoxypyridinoline, PYD pyridinoline 
"Comparison between fracture patients and contrais 
cally different, we showed only the Achilles+ SI and the 
Sahara QUI for combined strategies. The combinations of 
bone markers and QUS (Achilles+ SI or Sahara QUI) 
increased the AUC slightly but without statistically signif-
icant changes compared to either test alone. In sub-
analyses, the discriminatory power was higher for all tests 
when only the hip fracture subgroup was considered, with 
PYD exhibiting the highest AUC (0.75; 0.69-0.82); but, 
again, no single test was statistically better than any other. 
The combination of PYD and QUS was statistically better 
than QUS alone to discriminate between hip fracture 
patients and controls; however, this combination was not 
better than PYD alone (Table 2 and Fig. l ). Considering the 
arm fracture subgroup only, PYD and DPD were not 
discriminatory (data not shown). 
Table 3 shows OR with 95% CI and the number of 
women exposed to fractures versus women without fractures, 
associated with defined cutoffs for PYD, DPD, SI, and QUI. 
For PYD and DPD, the peak limits were >92.2 and 
17.8 pmol/µmol for the highest qumtile, and >63 and 13.5 
pmol/µmol for the premenopausal range, respectively. For 
the Achilles+ SI and Sahara QUI, the risk thresholds were 
~57 (%) and ~57.9 (unit) according to the lowest qumtile, 
and ~59.1 (%) and ~63 (unit) according to Hans et al. [20), 
respectively. Women with levels of bone markers above the 
highest quartile or the upper lhnit of the premenopausal 
Table 2 Area under the receiver operating-charactetistic curve (AUC) for predictive models of law-trauma non-vertebral fractures, with 95% 
confidence intervals (95%CI) 
Hip or arm fracture group (95% CI) Hip fractures group (95% CI) 
Urinary markers ofbone resorption PYD 0.62 (0.56-0.68) O. 75 (0.69-0.82) 
DPD 0.59 (0.53-0.65) 0.70 (0.63-0.78) 
Achilles+ heel ultrasound BUA 0.61 (0.55-0.67) 0.69 (0.62-0.77) 
SOS 0.64 (0.58-0.69) 0.68 (0.60-0.76) 
SI 0.64 (0.58-0.69) 0.70 (0.63-0.78) 
Sahara heel ultrasound BUA 0.64 (0.58-0.69) 0.68 (0.60--0.75) 
SOS 0.65 (0.60-0.71) 0.70 (0.62-0.78) 
QUI 0.65 (0.59-0.71) 0.69 (0.62-0.77) 
Combination Achilles+ and markers SI and PYD 0.66 (0.60-0.71) 0.76* (0.69-0.83) 
SI and DPD 0.65 (0.59-0.70) 0.74 (0.66-0.81) 
Combination Sahara and markers QUI and PYD 0.68 (0.62-0.73) 0.76** (0.69-0.83) 
QUI and DPD 0.67 (0.61-0.72) 0.74 (0.66-0.81) 
BUA broadband ultrasound attenuation, SOS speed of sound, SI stiffness index, QUI quantitative ultrasound index, DPD deoxypyridinoline, PYD 
pyridinoline 
*p<0.05 compared to Achilles+SI alone, **p<0.05 compared to Sahara QUI alone 
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Fig. 1 Receiver operating characteristic (ROC) curves for the 
discrimination of hip fractures with heel quantitative ultrasounds and 
urinary marker of bone resorption. Achilles+ SI stiffness index; PYD 
pyridinoline; Sahara QUI quantitative ultrasound index. a Combina-
tion of Achilles+ SI and PYD; b Combination of Sahara QUI and 
PYD 
range were at increased risk of sustaining a non-vertebral 
fracture, with OR of about 2. Achilles+ SI was significantly 
predictive only when the highest quaitile was considered and 
was slightly less predictive than the Sahara device. Because 
DPD was less predictive than PYD, data on the combination 
of QUS and bone markers are given only for PYD. The 
combinations of bone markers and QUS increased slightly 
the prediction of fracture with both risk threshold strategies, 
but with larger confidence intervals. Considering the hip 
fracture subgroup and the quartiles as high-risk thresholds, 
the combination of PYD and QUS ( either Achilles+ SI or 
Sahara QUI) had a higher predictive capacity than QUS 
alone; but it was not better than PYD alone (Table 3). 
Discussion 
In this nested case-control study including elderly women, 
we found that two urinaty markers of bone resorption, total 
PYD and total DPD, and two heel QUS, Achilles+ and 
Sahara, discriminate between low-trauma non-vertebral 
fracture patients and controls with about the same capacity. 
Combining the two QUS with bone resorption markers did 
not discriminate better than a single test between those at 
risk and those not at risk. Considering the hip fracture 
subgroup only, adding the measurement of urinary PYD to 
a heel QUS detennination improved discriminatory perfor-
mance of QUS alone, but not of PYD alone. 
Markers of bone resorption 
Bone resorption markers evaluate osteoclastic activity, 
which is the rate of bone destruction [3]. PYD and DPD 
are bone matrix components which stabilize the collagen 
molecule. They are released in the bloodstream and 
excreted in the urine during bone resorption. Of the 
different markers and measurement methods available, we 
used in this analysis total urinaiy PYD and DPD, both 
assessed by means of HPLC. Nowadays, direct immuno-
assays for PYD and DPD are widely used. The discrimi-
nato1y power of PYD and DPD assessed by HPLC can be 
extrapolated to immunoassays currently in use, as results 
of immunoassays reported for total PYD and DPD are 
highly correlated with those measured by HPLC (r=0.97 
for PYD ; r=0.95 for DPD) [30, 31). However, in clinical 
practice, the results of our study should not be extrapolated 
to guide the use of new sen.un resorption markers, like the 
Elecsys® f3-CrossLaps for example, as unpublished data 
from Roche Diagnostics have revealed only moderate 
correlation between urinary PYD or DPD (r about O. 7). In 
the SEMOF cohort, serum bone markers were not measured 
mainly for two reasons. First, urinary sampling is a safe, 
non-invasive and easily pe1formed technique. When evalu-
ating a screening test, simplicity and acceptability for 
patients are important criteria, and obtaining blood samples 
in the SEMOF cohort was difficult as most of the 
participants refüsed blood collection. Second, because the 
PYD and DPD found in urine largely are derived from 
skeletal tissues, independent of alimentation [32), at the time 
the protocol for the current study was drafted in 1997, these 
tests were considered the most sensitive markers of bone 
resorption [33). 
We found that elderly women with high levels of bone 
resorption markers were predisposed to osteoporotic frac-
tures with an OR of about 2. These results were consistent 
with previous studies, where high levels of bone markers 
(above the median, higher quattile, or levels above the 
premenopausal range) have been shown to contribute to 
fracture probability in elderly women [4-10) However, 
some recent repmts have shown controversial results. ln a 
prospective cohort study, Gerdhem et al. failed to identify 
any predictive capacity of urinary free DPD, measured by 
~ Springer 
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Table 3 Odds Ratios (OR) with 95% confidence intervals (95% CI) 
for non-vertebral fracture prediction and number (N) ofwomen in each 
mode! fçir a urinmy marker of bone _resoŒtion [pyridinoline (PYD)] 
and two heel quantitative ultrasounds [Achilles+ stiffness index (SI) 
and Sahara quantitative ultrasound index (QUI)], associated with 
various risk thresholds 
Quartile 
High PYD>92.2 pmol/µmol; high DPD> 17.8 pmol/µmol 
Low SI:S57 %; low QUI:S57.9 unit 
Hip or arm fracture group (195 fractures/173 controls) 
High PYD 
High DPD 
Low Achilles+ SI 
Low Achilles+ SI and high PYD 
Low Sahara QUI 
Low Sahara QUI and high PYD 
Hip fracture group (62 fractures/173 controls) 
High PYD 
High DPD 
Low Achilles+ SI 
Low Achilles+ SI and high PYD 
Low Sahara QUI 
Low Sahara QUI and high PYD 
Defined risk threshold 
OR (95 % CI) Positive test 
Fracture patients (N)/controls 
(N) 
2.4 (1.5-4.0) 62/28 
2.2 (1.3-3.6) 61/30 
1.9 (1.2-3.1) 61/33 
4.1 (l.6-10.2) 2516 
2.4 (1.5-4.0) 62/28 
5.4 (2.0-14.4) 27/5 
4.6 (2.4-8.7) 29/28 
4.2 (2.2-7.9) 29130 
3.3 (1.7-6.1) 27/33 
11.4 (4.3-30.4) 18/6 
3.3 (l.7-6.3) 24/28 
11.7 (4.1-33.6) 16/5 
High PYD>63 pmol/µmol; high DPD> 13.5 pmol/µmol: upper limit of premenopausal range 
Low SI:S59 .1 %; low QUI:S63 unit: thresholds from Hans et al. [20] 
Hip or arm fracture group (195 fractures/173 controls) 
High PYD 2.0 (1.3-3.1) 149/107 
High DPD 1.7 (1.1-2.6) 119/82 
Low Achilles+ SI 1.5 ( 1.0-2.4) 71147 
Low Achilles+ SI and high PYD 1.9 (1.2-3.1) 60133 
Low Sahara QUI 2.1 (1.4-3.2) 99/57 
Low Sahara QUI and high PYD 2.4 (1.5-3.8) 168/125 
Hip fracture group (62 fractures/173 contrais) 
High PYD 7.0 (2.7-18.4) 57/107 
High DPD 3.8 (2.0-7.4) 48/82 
Low Achilles+ SI 2.5 (1.4-4.6) 30/47 
Low Achilles+ SI and high PYD 4.0 (2.1-7.4) 30/33 
Low Sahara QUI 3.2 (1.8-5.9) 38/57 
Low Sahara QUI and high PYD 5.1 ( 2.7-9.4) 37/39 
N egati ve test 
Fracture patients (N)/controls 
(N) 
133/145 
134/143 
134/140 
170/167 
133/145 
168/168 
33/145 
33/143 
35/140 
44/167 
38/145 
46/168 
46166 
76/91 
124/126 
135/140 
96/116 
27/48 
5166 
14/91 
321126 
32/140 
24/116 
25/134 
immunoassay, during a mean 4.6 years of follow-up for 
osteoporosis fractures in ambulato1y elderly women [34]. 
Examining different bone turnover markers, Chen et al. 
found no difference between fracture cases and controls in 
older women and men living in residential care facilities 
[35]; and, in a convenient prospective cohort of elderly 
women with known osteoporosis and receiving treatment, 
Glüer et al. detected no difference between patients with or 
without incident vertebral fractures [36]. Mainly because of 
the large pre-analytical variability of bone markers and 
differences in the populations studied, comparing the 
results of these rep01is is fraught with difficulty. 
No generally accepted threshold exists to define "high 
turnover rate," and most current guidelines do not give 
clear recommendations for the clinical use of bone 
resorption markers. To address this concern, we investigat-
ed different thresholds for bone markers. The upper limit of 
premenopausal range is a convenient and clinically appli-
cable threshold. Values were provided by a laborat01y kit, 
and they were Jess elevated than the median for PYD and 
about the same as the median for DPD. Thus, bone marker 
levels above the highest quaiiile identified patients at high 
risk for fracture and appeared to be more predictive than 
using the upper limit of premenopausal range because of 
the smaller number of patients detected. However, when 
interpreting the results in light of confidence intervals, there 
was no difference between threshold strategies. At the 
opposite end, a lower cutoff may be used when the goal is 
to rnle out any increased risk of fracture. Our data show that 
the absence of any elevation in PYD above the premeno-
~ Springer 
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pausal range in elderly women strongly decreases the 
probability of hip fracture, as only five women with a 
negative test sustained a hip fracture. 
We also found that PYD was slightly more discrimina-
tive for the hip or arm fracture group than DPD. 
Physiologically, DPD is more specific for bones than 
PYD [37], so that a higher discriminat01y capacity should 
have been expected. However, previous studies comparing 
the discriminat01y power of PYD and DPD for postmen-
opausal osteoporosis have been inconsistent [38-40]. 
Combining markers of bone resorption and heel 
quantitative ultrasound 
The use of heel QUS together with PYD added nothing to 
either test pe1formed alone with respect to detecting women 
at risk for low-trauma non-vertebral fractures. However, in 
subgroup analysis, for the discrimination of hip fractures 
only, our results suggest that increased bone resorption 
might add complementmy information to QUS measure-
ments, identifying high-risk patients who were missed by 
QUS. To our knowledge, this improvement in the discrim-
inat01y capacity of the serial combination of QUS and 
bone resorption markers has not been evident in other 
studies. Gamero et al. found that the serial detection of 
C-telopeptide breakdown products (CTX) above the pre-
menopausal range and low BMD is an improvement over 
the accuracy of a single test as a predictor of hip fracture, 
but they found no advantage of combining heel ultrasound 
and CTX [ 1 J ]. However, in our study, performing PYD 
assessment alone would be as discriminative as the 
combination of the both PYD and QUS. Moreover, the 
apparent contrast between the AUC results, demonstrating 
no additive value when QUS and resorption markers are 
combined, and the large OR for those with both low QUS 
and high resorption markers, with quartile as threshold, 
might be explained by the consecutive selection of a small 
number participants at ve1y high-risk of fracture, represent-
ing a small proportion of the study participants, as reflected 
by the large confidence intervals of OR (Table 3). 
Considered the gold standard for osteoporosis assess-
ment, BMD was not measured in the SEMOF cohort. 
Instead, we used different heel QUS as the reference tests 
for fracture prediction. However, heel QUS has been 
proven to predict osteoporotic fractures as well as BMD 
measurements in elderly women [27, 28, 41], and because 
QUS is relatively inexpensive, transportable, and ionizing 
radiation-free, there is a growing interest in its use in many 
countries. High levels of correlation (r>0.8) have been 
rep01ied between Achilles and Sahara parameters. The 
Achilles QUS is considered the "reference device" [26], 
because of its use in most of the validation studies. In our 
analyses, we found that Achilles+ SI was slightly less 
discriminatory than Sahara QUI. Cross-sectional studies 
comparing the two devices uncovered better results with 
Achilles+ SI for hip fracture prediction [21, 42], but the 
results are inconsistent for vertebral fracture prediction [ 43]. 
Our study has limitations. Urine sample collection was 
standardized, so as to control for the timing of collection; 
nonetheless, because significant diurnal variations exist in 
the levels of biochemical bone markers, within-subject 
variability could not be avoided completely. The day-to-day 
variation in the urinary excretion of PYD and DPD also is 
reported to be a major source of within-subject variability 
[44], which also cou!d affect the reproducibility of results. 
AUC and OR were higher in the hip fracture subgroup than 
in the hip or ann fracture group. This increased predictive 
ability could be related to more advanced osteoporosis in 
women who subsequently sustain a hip fracture. This 
difference in severity of disease may have improved the 
prediction power. Thus, the results we obtained within the 
hip fracture subgroup should not be extrapolated to justify 
similar screening in populations with Jess advanced disease. 
In addition, the number of hip fractures investigated was 
relatively low, so that the confidence intervals were broad. 
This reflects the need for cautions interpretation of our results 
when considering any individual patient. Finally, cases and 
contrais were matched on BMI, and its effect on QUS 
measurements or bone turnover assessments have not been 
investigated. Possible overmatching could have reduced the 
differences observed between cases and controls. 
Strategies to improve the identification of women at risk 
for fracture are being developed, using multiple risk factors, 
including clinical risk factors, QUS, and BMD measure-
ments [45]. Our study increases the quantity of evidence 
supporting the relatively equal capacity of urinary bone 
resorption markers and heel QUS to detect elderly ambulant 
women at risk for low-trauma non-vertebral fractures 
relative to matched controls. However, the serial combina-
tion of the both tests added no complementmy discrimina-
to1y information compared to either test used alone. These 
data, in turn, may help in the design of efficient strategies to 
evaluate fracture risk in elderly women. 
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